Form 4: Cytokinetics CEO Robert Blum Executes Stock Sale

Cytokinetics President and CEO Robert I. Blum sold 7,500 shares of common stock on April 15, 2026.

Summary

• Robert I. Blum, President and CEO of Cytokinetics, sold 7,500 shares of common stock.
• The transaction was executed at a price of $65.38 per share.
• The sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, Mr. Blum retains direct ownership of 415,330 shares.
• Mr. Blum maintains indirect ownership of 4,166 shares held across two irrevocable trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted via a pre-established 10b5-1 plan, which is standard practice for corporate executives.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 program, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the CEO's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market, regardless of the existence of a 10b5-1 plan.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine in the biotechnology sector and generally do not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executive equity management to ensure compliance with SEC regulations.

Related Party Transactions

• The filing notes indirect ownership of shares held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the CEO's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Cytokinetics, CYTK, Insider Trading, Form 4, Robert Blum, Biotech